ADARx Pharmaceuticals

Intangible assets are the core: ADARx discloses differentiated sequence engineering (MST) and cell-type delivery (CTD) that claim higher potency and durability, plus extrahepatic targeting to adipose and neurons. Patent filings cover platform and programs, with expected expiries into the 2040s.

However, foundational GalNAc-conjugation IP has dense prior art risk, which ADARx itself flags. No network effects exist. Switching costs would emerge only post-approval if dosing is truly semiannual and adherence improves. Efficient scale is limited until commercialization.

Overall, there is credible technology and IP depth but contested fields and overlapping claims temper durability.